Business Context and Reporting Period
This Form 8-K is a current report filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on January 13, 2023. The registrant is a Delaware corporation headquartered in Palo Alto, California, with common stock (ATNF) and warrants (ATNFW) listed on The NASDAQ Stock Market LLC. The filing reports a material event under Item 8.01 regarding a new commercial agreement.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or balance sheet data. The only financial metric disclosed is a forward-looking cost estimate:
- Anticipated Expenditure: Approximately $900,000 to $1,000,000 over the next three quarters.
- Use of Funds: Costs associated with the Kinexum contract, MHRA filing, and regulatory preparation.
Material Changes
The primary material change reported is the execution of a Master Services Agreement (MSA) with Kinexum on January 13, 2023. Under this agreement, Kinexum will assist the Company with:
- Conditional Marketing Authorisation (CMA).
- Marketing Approval Application (MAA).
- Submission to the UK Medicines and Healthcare products Regulatory Agency (MHRA).
- Regulatory support for the planned use of adalimumab to treat progressive early-stage Dupuytren's disease.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company expects to submit the CMA and MAA to the MHRA in connection with its adalimumab treatment plan. Management has provided a specific budget outlook for the upcoming three quarters to cover these regulatory activities.
Risks and Contingencies: The filing does not explicitly detail new risks beyond the standard regulatory approval process implied by the MSA. The success of the business plan is contingent upon the MHRA's acceptance of the application and the efficacy of the proposed treatment.
Investor Verification Checklist
- Verify the exact scope of services and payment terms in the MSA with Kinexum (Exhibit 99.1 press release).
- Confirm the Company's current cash position to ensure it can fund the anticipated $900,000–$1,000,000 expenditure over the next three quarters.
- Monitor the timeline for the submission of the CMA and MAA to the UK MHRA.
- Review the clinical data supporting the use of adalimumab for Dupuytren's disease to assess regulatory approval probability.